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Abstract Alzheimer disease (AD) is one of the major unresolved health burdens accompanying the increase
	 in	 life	expectancy.	The	great	paradigm	shift	 for	 this	disease	has	resulted	from	finding	amyloid	de-
position and neurobrillary degeneration 20 years and 10 years, respectively, prior to onset of the typical clinical 
memory	 loss	 symptoms.	 The	 advent	 of	 AD	 biomarkers	 has	 enabled	 a	molecular	 definition	 of	 AD,	making	 the	
clinical	definition	almost	dispensable.	Various	types	of	AD	biomarkers	are	available	in	our	country.	Each	biomarker	
reflects	a	particular	process	and	stage	of	 the	disease.	Although	costs	restrict	 their	use,	 the	biomarker	analysis	
may	be	justified	in	certain	clinical	scenarios,	such	as	an	early	onset	or	an	atypical	presentation	of	the	disease.	
Today, the usefulness of biomarkers in AD clinical research is beyond question. Furthermore, the introduction of 
biomarkers	into	medical	practice	has	led	to	significant	changes	in	therapeutic	interventions,	even	in	the	absence	
of disease-modifying drugs. 
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antes, de que aparezca la sintomatología clínica típica de pérdida de memoria. La aparición de los biomarcadores 
permitió	 reestructurar	 el	 concepto	 de	 la	EA,	 intentándose	 llegar	 a	 una	 definición	molecular	 de	 la	misma	 casi	
prescindiendo de la emblemática clínica. Existen distintos tipos de biomarcadores de EA disponibles en nuestro 
país.	Cada	uno	nos	habla	de	un	proceso	y	un	momento	distinto	de	 la	enfermedad.	Aunque	su	uso	clínico	aún	
se	encuentra	restringido	por	cuestiones	de	costos,	existen	escenarios	particulares	en	donde	sí	se	justifica,	casi	
siempre en relación a presentaciones clínicas atípicas o de comienzo muy temprano. Sin embargo, hoy en día ya 
nadie discute que son imprescindibles en investigaciones clínicas sobre EA. La incorporación de biomarcadores 
en	la	práctica	médica	ha	generado	cambios	significativos	en	la	intervención	terapéutica	de	los	pacientes,	incluso	
en	un	contexto	en	el	que	todavía	no	hay	medicamentos	modificadores	de	la	enfermedad.
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The Alzheimer disease (AD) is one of the main un-
resolved health burdens accompanying the increase in 
life expectancy and has become a crucial public health 
problem1. One out of every two individuals over the age 
of 80 will develop the disease with the ensuing impact on 
their family and society2.
The main pathophysiological mechanism underlying 
AD involves increase in Aβ peptide species, ultimately 
leading	to	extracellular	amyloid	deposits	and	neurofibril-
lary degeneration, secondary to intraneuronal abnormal 
tau protein hyperphosphorylation. In 2012, Bateman et al.3 
showed	that	amyloid	deposits	and	neurofibrillary	degen-
eration were present 20 and 10 years before the onset of 
memory decline, respectively.
	As	a	result	of	these	findings,	the	course	of	AD	was	
divided into three stages –presymtomatic, mild cogni-
tive	impairment,	and	dementia−	with	the	presymtomatic	
phase currently attracting major research efforts on AD 
pathophysiology, treatment, and prevention.
Prior to the introduction of biomarkers, the clinical di-
agnosis (NINCDS-ADRDA criteria) was limited to possible 
or	probable	AD,	given	that	diagnosis	was	only	confirmed	
in post-mortem brain tissue histopathology 4.
Biomarkers	are	defined	as	objective,	quantifiable	pa-
rameters which allow in vivo assessment of pathophysi-
ological disease traits. Current biomarkers for AD include: 
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such	as	brain	MRI	and	hippocampal	volume	analysis;	3)	
functional neuroimaging of metabolic activity such as 18F-
fluorodesoxyglucose	(FDG)	PET	and	protein-identifying	
neuroimaging such as amyloid PET and tau PET. 
Based	on	 the	application	of	 these	specific	biomark-
ers, the US National Institute of Aging and Alzheimer’s 
Association revised the accepted diagnostic criteria for 
AD5-8, which led to two important changes. First, the use 
of biomarkers allowed a formal separation of the different 
disease stages to include mild cognitive impairment, thus 
providing	greater	sensitivity	and	specificity	to	the	detection	
of early AD. Second, the application of biomarker results 
allowed to achieve higher diagnostic certainty, in relation to 
the underlying neuropathological changes present in AD.
In	2018,	a	new	biomarker-based	biological	classifica-
tion,	the	A/T/N	(Amyloid/Tau/	Neurodegeneration)	system,	
was published9, in which “A” refers to the presence of 
β-amyloid biomarker (detected on amyloid PET or as-
saying CSF Aβ42	 level);	 “T”	 refers	 to	 the	value	of	a	 tau	
biomarker (measured in CSF phospho-tau assay, or on tau 
PET);	and	“N”	refers	to	biomarkers	of	neurodegeneration	
or neuronal injury (evaluated  on [18F]-fluorodeoxyglucose-
PET, structural MRI, or measuring total tau in CSF). This 
classification	allows	a	pathophysiological	categorization	
and a clearer prediction of patient outcome9. 
The introduction of biomarker results has profoundly 
influenced	AD	diagnosis,	prognosis	and	treatment,	since	
it allows the detection of very early stages in individuals 
presenting mild AD symptoms without dementia (prodro-
mal AD), or even at pre-symptomatic stages.
Thus, with pharmacological treatments becoming avail-
able for very early stages of the AD, the major challenge 
becomes	finding	simpler	biomarkers.	We	hope	that	in	the	
not too distant future the value of their potential applica-
tion extends to all clinical scenarios for which they may 
prove useful.
Alzheimer´s disease biomarkers in fluids
A better understanding of the disease mechanisms in-
volved in AD has allowed the development of different 
types	 of	 fluid	 biomarkers.	CSF	has	 become	a	 primary	
viable source, given its close contact with the CNS at the 
extracellular compartment level. However, because of the 
invasive nature of the spinal tap, patients are reluctant to 
undergo testing, and repeated sampling is poorly toler-
ated, which is why biomarkers in blood are now being 
investigated and validated10.
Three key CSF biomarkers have been included in 
several guidelines and research manuals. These are: 
β-amyloid 42 (Aβ1-42), total tau (t-tau) and threonine18-
phosphorylated tau (p-tau). Altered CSF levels of any of 
these are recognized diagnostic evidence of underlying 
brain disease compatible with AD8. Added prognostic 
value has also been reported for these molecules as 
evidence of disease progression in individuals who 
remain cognitively intact8 as well as in individuals with 
mild cognitive impairment6. Also, Aβ1-42 levels may help 
to distinguish AD from other clinical conditions such as 
frontotemporal dementia. 
In recent years, new biomarkers have been described 
as related to other pathophysiological aspects such as 
vascular dysfunction, neuronal and synaptic integrity 
and	neuroinflammation,	 to	 name	a	 few.	 In	 this	 regard,	
neurofilament-light	chain	(NfL),	an	intermediate	filament	
of the neuronal cytoskeleton, which is abundant in axons, 
has been recognized as a marker of neuronal damage, 
increasing in both CSF and blood as a result of different 
neurodegenerative diseases11-14.	 Although	 not	 specific	
for AD, NfL blood levels could be useful for screening 
purposes. When high NfL levels are detected, subjects 
could then be tested for known AD biomarkers, namely 
Aβ1-42, t-tau or p-tau in CSF, or PET PiB.
Other biomarkers, such as neurogranine (a marker of 
synapse	dysfunction)	or	markers	of	 inflammation	 likeT-
REM2 and YKL-40, require more exhaustive validation 
before they are included in the panel of accepted AD 
biomarkers12.
Aside from their role in diagnosis, biomarkers could 
soon become indispensable tools for the development of 
future AD therapies. Currently, their use in clinical trials 
improves	 the	 classification	of	 participants	 according	 to	
the underlying disease, allows staging the disease more 
precisely and also allows a better and earlier evaluation 
of treatment response13.
Prior to implementation, new biomarkers will require 
validation for different conditions or stages and different 
applications such as screening, diagnosis, treatment 
monitoring, among others15. 
Alzheimer´s disease biomarkers in 
neuroimaging
Morphological imaging, using both magnetic resonance 
(MRI) and computed tomography (CT), as well as mo-
lecular methods like positron emission tomography (PET) 
and single photon emission tomography (SPECT), play an 
important role in early diagnosis and in non-invasive in vivo 
follow up of patients with neurodegenerative syndromes. 
Brain deposits of the abnormal proteins Aβ and tau can be 
detected using PET and neuronal dysfunction measured 
by	analyzing	brain	glucose	metabolism	(FDG).	Cerebral	
perfusion evaluated by SPECT shows good correlation 
with metabolic changes.
AD is the most prevalent neurodegenerative disease 
and presents a particular molecular and structural neuro-
imaging	profile,	in	which	cortical	and	extraneuronal	amy-
loid deposits precede the emergence of clinical symptoms 
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by 20 years. PET using amyloid-labeling tracers (11C-PIB, 
18F-Flutemetamol and 18FAV45,	among	others),	represents	
a sensitive tool for early detection of abnormal brain de-
posits in the areas most often affected, namely the bilateral 
frontal and parietal lobes, the lateral temporal cortex and 
striatal regions. Although detection of amyloid implies 
greater disease risk, or increased diagnostic certainty, it 
is important to note that amyloid deposits are present in 
up to 30% of cognitively normal individuals.
The	 tau	protein	 is	 found	 in	neurofibrillary	 tangles	at	
intraneuronal level, and its hyperphosphorylated forms 
are	specific	to	AD.	On	PET	imaging,	different	tracers	still	
under development can be detected with varying degrees 
of	 sensitivity	 and	 specificity.	 Flortaucipir	 (18FAV1451)	
has been tested in our country in the ADNI-Arg cohort 
of patients with clinical diagnosis of AD followed for 5 
years (Alzheimer Disease Neuroimaging Initiative – Ar-
gentina);	 the	study	showed	higher	concentration	 in	 the	
mesial temporal lobe. Neuronal dysfunction explored us-
ing 18FDG-PET,	a	marker	of	neurodegeneration,	showed	
bilateral areas of hypometabolism in the temporal lobe, 
the precuneus, the posterior cingulated cortex, and the 
parietal	lobe.	Altogether,	these	findings	tend	to	show	the	
following chronological sequence of tracer uptake during 
preclinical	phases:	first	amyloid	deposition,	then	tau	de-
position, and later neuronal dysfunction8. As an example, 
Fig. 1 shows images of brain PET scans illustrating the 
biomarker	findings	characteristic	of	the	ATN	classification.
Structural brain MRI reveals the presence of reduced 
hippocampal	 volume,	 as	well	 as	 area-specific	 cortical	
atrophy (parahippocampal gyrus, amygdala, superior, 
medial and inferior temporal gyri, superior parietal lobe and 
posterior cingulate cortex). Both are considered biomark-
ers of neurodegeneration generally appearing later than 
others, that is, during symptomatic stages of the disease. 
A	specific	software	is	used	to	measure	findings	compared	
to quantitative values of standardized digital atlas images, 
which are available in most local imaging centers.
The functional imaging technique most recently incor-
porated is the resting state MRI (rs-fMR), in which BOLD 
signal detection generates resting state images (without 
any type of activity). This allows “connections” between dif-
ferent areas to be studied by correlating temporal neuronal 
activity between different areas of the brain cortex. The 
areas of the greatest synchronicity or correlation represent 
closely linked neuronal networks. To date, rs-fMRI results 
have shown different connectivity patterns in AD patients 
compared to normal controls, as well as in patients with 
mild cognitive impairment and even at preclinical stages 
of the disease16.
In summary, a series of sequential and concurrent 
events need to be taken into consideration, both spatially 
and chronologically, which include detection of Aβ42 and 
phospho-Tau, volumetric analysis, hypometabolic areas 
and connectivity disruption. Imaging techniques provide 
information on different “stages or phases” of the AD 
continuum, generating new opportunities for eventual 
treatment interventions.
Clinical utility of biomarkers in
Alzheimer´s disease
Based on all of the above, it seems clear that the biomark-
ers have improved the diagnosis of AD beyond clinical 
findings,	and	have	shown	that	the	preclinical	stages	of	the	




cognitive impairment patients n =1 3, and patients with 
dementia of the Alzheimer type, n = 1217).
Today,	 the	 value	 of	 this	 classification	 in	 clinical	 tri-
als and clinical research is beyond question. However, 
numerous limitations hinder its application in routine 
clinical practice, in particular for developing countries in 
Latin-American,	mainly	due	to	financial	constraints,	limited	
experience and validation, and restricted clinical access for 
most of the region. A recent survey has shown however, 
that it is nevertheless already being used in Argentina, 
Brazil, Colombia, Chile, Mexico and Uruguay, among 
other countries18.
If no disease-modifying drug is available, what is the 
point of applying biomarkers in clinical practice? Several 
papers	 have	 recommended	 their	 use	 in	 specific	 situa-
tions19. There is general agreement that in early-onset 
disease (under 65 years of age) as well as in atypical 
forms of AD, which often also present before 65, biomark-
ers could be useful. Less anosognosia is present in this 
age group, which is more concerned on diagnosis and still 
at	very	productive	stages	of	life.	Diagnostic	confirmation	
would allow making life-changing decisions and improve 
differential diagnosis with other radically different types of 
disease. Finally, genetic implications may exist for other 
family members, (i.e. autosomal dominant forms of AD). 
One could also add groups of patients in whom AD is 




ity, i.e. for posterior cortical atrophy), the opposite occurs 
in other clinical conditions (pretest likelihood is low), hence 
the value of biomarkers19. 
The	findings	of	the	IDEAS	protocol,	conducted	on	18	
000 imaging studies in US centers to evaluate the clinical 
utility of amyloid PET results, have recently been pub-
lished20.	Briefly,	the	study	showed	that	the	participating	
physicians	modified	prescriptions	or	changed	their	clinical	
management in 60% of the patients based on imaging 
results. This shows that vis-à-vis the diagnostic uncertainty 
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•	 A-T-(N-)	PET	images	of	amyloid	and	tau	do	not	show	tracer	uptake.	Normal	metabolism	on	FDG	PET.	Images	correspond	
to normal subjects
•	 A+T-(N-) PET image is positive for amyloid, cortical tracer uptake is visible. Tau PET is negative and metabolism normal 
on	FDG.	These	images	correspond	to	the	initial	stage	of	cerebral	amyloidosis	in	pre-symptomatic	AD
•	 A+T+(N-)	PET	image	is	positive	for	amyloid	and	tau,	cortical	uptake	is	seen	for	both.	PET	FDG	shows	normal	metabolism.	
These images correspond to the second stage of pre-symptomatic AD with amyloid and tau deposits
•	 A+T+(N+)	This	case	shows	cortical	amyloid	and	tau	deposits	and	posterior	hypometabolism	on	FDG	PET.	Typical	images	
in AD patients
•	 A+T-(N+) This panel shows anterior cortical positivity on amyloid PET, Tau PET is negative y and there is posterior hypo-
metabolism	mainly	on	the	right	side	on	FDG	PET.	This	case	is	compatible	with	AD	associated	to	non-AD	pathology





and posterior hypometabolism compatible with non-AD pathology
Fig.	 1.–	ATN	classification	based	on	brain	PET	 (amyloid,	 tau	and	FDG),	FLENI	
Neuroimaging  database






autopsy material. The diagnosis was based on the detailed 
presence, density and distribution of the characteristic 
lesions, namely extracellular amyloid plaque and intraneu-
ronal	neurofibrillary	degeneration.	These	criteria	were	later	
refined	and	quantified	in	an	attempt	to	include	other	lesions	
that usually coexist in the aging brain and affect cognition.
The discovery of biomarkers which can report in vivo 
on the presence of these deposits has radically changed 
neurodegeneration diagnosis. However, as is common in 
biomedicine, technical advances come together with prob-
ably even more relevant conceptual changes. In the case 
of	AD,	this	has	led	to	a	new	definition	of	the	disease,	sepa-
rating	it	from	dementia	as	a	single	clinical	finding,	which	
can develop during the course of several other concurrent 
diseases. Diagnosis today is determined by detection of 
amyloid, T-tau and P-tau. It is not known whether these 
abnormal proteins actually cause the disease, but they 
are	nevertheless	their	defining	feature.	Protein	deposits	
make	AD	a	unique	and	specific	neurodegenerative	disor-
der, separating it from other conditions causing dementia. 
This differentiation is key, since it allows examination of 
chronological events leading to clinically evident effects on 
cognition as a continuum, which includes intact subjects 
amenable to potential treatment strategies. In the not too 
distant future, taxonomic consequences resulting from 
biomarker use are foreseeable, linking the nosology to 
an underlying molecular abnormality, which in turn, may 
become a potential objective for targeted therapies.
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